Skip to main content
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. — Investor Relations & Filings

Ticker · TARA ISIN · US74365U1079 LEI · 549300VWUGH3220TG273 US Professional, scientific and technical activities
Open in API
Filings indexed 758 across all filing types
Latest filing 2026-05-28 Capital/Financing Update
Country US United States of America
Listing US TARA

About Protara Therapeutics, Inc.

https://protaratx.com/

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for cancer and rare diseases. The company's lead candidate is TARA-002, an investigational cell therapy based on the immunopotentiator OK-432. TARA-002 is being evaluated for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), for which it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Protara's pipeline also includes IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on parenteral support who are choline deficient, with the potential to become the first FDA-approved intravenous choline formulation for this patient group.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 98% confidence The document is a Form 424B5 prospectus supplement to a shelf registration on Form S-3, detailing the terms of an at-the-market equity offering of $100 million of common stock through TD Cowen. It is related to a capital raising and financing activity (the sale of newly issued shares). Therefore, it falls under Capital/Financing Update (CAP).
2026-05-28 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 85% confidence The document is a Securities and Exchange Commission registration statement on Form S-3, including a base prospectus for up to $300 million of common stock, preferred stock, debt securities and warrants. It is a prospectus used to register and facilitate a capital offering under the Securities Act of 1933. This is not an earnings release or management discussion, nor a proxy, audit report or 10-K. It clearly relates to a financing transaction, making it a Capital/Financing Update. Therefore, the correct classification is CAP.
2026-05-13 English
10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a short (4,142 characters) Form 8-K current report under the Exchange Act that does not itself include any substantive financial data but instead furnishes a press release (Exhibit 99.1) announcing results of operations for the quarter. It simply states the press release is attached and does not present the full results or analysis. Under the “menu vs meal” rule, this is an announcement that a report (the earnings press release) has been published and is being furnished. Thus, it best matches the Report Publication Announcement category (RPA).
2026-05-13 English
8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Protara Therapeutics, Inc. It reports a specific event related to clinical trial results and the exercisability of common stock purchase warrants. The document is dated March 30, 2026, and includes no financial statements or detailed financial analysis. It is a regulatory announcement of a material event rather than a full financial report or earnings release. The document is relatively short (4679 characters) and serves as a current report to inform investors of a significant corporate event. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-03-30 English
8-K - PROTARA THERAPEUTICS, INC. (0001359931) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Protara Therapeutics, Inc. It includes disclosures about a press release, investor presentation, corporate deck, and poster presentations related to updated interim clinical trial data. The document references the posting of these materials on the company's website and their use in a conference call and webcast. The content focuses on interim clinical trial results and upcoming trial enrollment plans, but does not contain comprehensive financial statements or detailed financial analysis. The document is not an earnings release, annual report, or interim financial report. It is a regulatory filing providing updates on clinical trial progress and related investor communications. Therefore, the appropriate classification is Regulatory Filings (RNS). The confidence in this classification is high given the clear identification as a Form 8-K and the nature of the content.
2026-02-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.